Alexion Pharmaceuticals, Inc. (ALXN) Position Raised by Twin Capital Management Inc.

Twin Capital Management Inc. increased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.2% in the 1st quarter, Holdings Channel reports. The firm owned 47,170 shares of the biopharmaceutical company’s stock after acquiring an additional 80 shares during the quarter. Twin Capital Management Inc.’s holdings in Alexion Pharmaceuticals were worth $6,376,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ALXN. Whittier Trust Co. lifted its stake in Alexion Pharmaceuticals by 20.4% in the first quarter. Whittier Trust Co. now owns 472 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 80 shares during the last quarter. Wedbush Securities Inc. lifted its stake in Alexion Pharmaceuticals by 1.5% in the fourth quarter. Wedbush Securities Inc. now owns 5,467 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 83 shares during the last quarter. LS Investment Advisors LLC lifted its stake in Alexion Pharmaceuticals by 1.4% in the first quarter. LS Investment Advisors LLC now owns 6,689 shares of the biopharmaceutical company’s stock valued at $904,000 after buying an additional 94 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its stake in Alexion Pharmaceuticals by 0.3% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,396 shares of the biopharmaceutical company’s stock valued at $4,920,000 after buying an additional 95 shares during the last quarter. Finally, Utah Retirement Systems lifted its stake in Alexion Pharmaceuticals by 0.3% in the fourth quarter. Utah Retirement Systems now owns 39,903 shares of the biopharmaceutical company’s stock valued at $3,885,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.

A number of brokerages have weighed in on ALXN. TheStreet upgraded Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. BidaskClub cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $186.00 price target (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Raymond James assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, April 10th. They set an “outperform” rating and a $161.00 price target for the company. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $162.25.

NASDAQ ALXN traded down $3.16 during trading hours on Friday, hitting $128.61. 25,669 shares of the company’s stock were exchanged, compared to its average volume of 1,524,850. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86. The company has a market capitalization of $29.55 billion, a PE ratio of 18.17, a price-to-earnings-growth ratio of 1.08 and a beta of 1.53. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the business posted $1.68 earnings per share. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. Equities analysts predict that Alexion Pharmaceuticals, Inc. will post 8.6 EPS for the current year.

In related news, CAO Daniel Bazarko sold 2,000 shares of the stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $126.00, for a total transaction of $252,000.00. Following the transaction, the chief accounting officer now directly owns 5,020 shares in the company, valued at $632,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/alexion-pharmaceuticals-inc-alxn-position-raised-by-twin-capital-management-inc.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: The primary rules of Elliott Wave theory

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.